Skip to main navigation
Skip to search
Skip to main content
University of Birmingham Home
Help & FAQ
Home
Research output
Profiles
Research units
Projects
Activities
Datasets
Equipment
Prizes
Press/Media
Search by expertise, name or affiliation
Pegvisomant: a new treatment modality for acromegaly
Niki Karavitaki
, John A H Wass
Metabolism and Systems Science
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Pegvisomant: a new treatment modality for acromegaly'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
New Treatment Options
100%
Growth Factors
100%
Insulin-like
100%
Pegvisomant
100%
Novel Treatments
33%
Therapeutic Potential
33%
Growth Hormone Receptor
33%
Signaling Events
33%
Number of Patients
33%
Receptor Signaling
33%
Disease Activity
33%
Dopamine Agonist
33%
Tumor Size
33%
Pituitary Tumor
33%
Treatment Options
33%
Multisystem Disease
33%
Liver Enzymes
33%
Growth Hormone
33%
High Cost
33%
Medical Therapy
33%
Second-line Treatment
33%
Somatostatin Analogs
33%
Therapy Goals
33%
Medical Treatment
33%
Growth Hormone Receptor Antagonist
33%
Radiotherapy Treatment
33%
Tumor Characteristics
33%
Enzyme Level
33%
High Failure Rate
33%
Surgery Treatment
33%
Excessive Growth
33%
Medicine and Dentistry
Acromegaly
100%
Somatomedin C
100%
Pegvisomant
100%
Combination Therapy
66%
Growth Hormone Receptor
66%
Diseases
66%
Health Care Cost
33%
Receptor
33%
Neoplasm
33%
Disease Activity
33%
Pituitary Tumour
33%
Liver Enzyme
33%
Growth Hormone
33%
Dopamine Agonist
33%
Somatostatin Derivative
33%
Hormone Receptor Blocking Agent
33%
Internalization
33%
Radiation Therapy
33%
Pharmacology, Toxicology and Pharmaceutical Science
Somatomedin C
100%
Acromegaly
100%
Pegvisomant
100%
Combination Therapy
66%
Growth Hormone Receptor
66%
Diseases
66%
Receptor
33%
Neoplasm
33%
Dopamine Receptor Stimulating Agent
33%
Disease Activity
33%
Growth Hormone
33%
Hypophysis Tumor
33%
Somatostatin Derivative
33%
Hormone Receptor Blocking Agent
33%
Liver Enzyme
33%
Neuroscience
Insulin-Like Growth Factor 1
100%
Acromegaly
100%
Pegvisomant
100%
Growth Hormone Receptor
66%
Receptor
33%
Internalization
33%
Receptor Antagonist
33%
Dopamine Agonist
33%
Pituitary Tumour
33%
Bovine Somatotropin
33%
Somatostatin Derivative
33%
Liver Enzyme
33%
Growth Hormone
33%
Radiation Therapy
33%